EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 28 / No 3 (Mars 2012) Med Sci (Paris), 28 3 (2012) 258-261 References
Free Access
Issue
Med Sci (Paris)
Volume 28, Number 3, Mars 2012
Page(s) 258 - 261
Section Nouvelles
DOI https://doi.org/10.1051/medsci/2012283010
Published online 06 April 2012
  1. Bressac de Paillerets B, Avril MF, Chompret A, Demenais F. Genetic and environmental factors in cutaneous malignant melanoma. Biochimie 2002 ; 84 : 67–74. [CrossRef] [PubMed] [Google Scholar]
  2. Demenais F, Mohamdi H, Chaudru V, et al. Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study. J Natl Cancer Inst 2010 ; 102 : 1568–1583. [CrossRef] [PubMed] [Google Scholar]
  3. Bertolotto C, Lesueur F, Giuliano S, et al. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature 2011 ; 480 : 94–98. [CrossRef] [PubMed] [Google Scholar]
  4. Yokoyama S, Woods SL, Boyle GM, et al. A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 2011 ; 480 : 99–103. [CrossRef] [PubMed] [Google Scholar]
  5. Carreira S, Goodall J, Denat L, et al. Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev 2006 ; 20 : 3426–3439. [Google Scholar]
  6. Cronin JC, Wunderlich J, Loftus SK, et al. Frequent mutations in the MITF pathway in melanoma. Pigment Cell Melanoma Res 2009 ; 22 : 435–444. [Google Scholar]
  7. Garraway LA, Widlund HR, Rubin MA, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005 ; 436 : 117–122. [CrossRef] [PubMed] [Google Scholar]
  8. Maubec E, Chaudru V, Mohamdi H, et al. Characteristics of the coexistence of melanoma and renal cell carcinoma. Cancer 2010 ; 116 : 5716–5724. [CrossRef] [PubMed] [Google Scholar]
  9. Cheli Y, Ohanna M, Ballotti R, Bertolotto C. Fifteen-year quest for microphthalmia-associated transcription factor target genes. Pigment Cell Melanoma Res 2010 ; 23 : 27–40. [Google Scholar]
  10. Sarge KD, Park-Sarge OK. SUMO and its role in human diseases. Int Rev Cell Mol Biol 2011 ; 288 : 167–183. [CrossRef] [PubMed] [Google Scholar]
  11. Zhang YQ, Sarge KD. Sumoylation regulates lamin A function and is lost in lamin A mutants associated with familial cardiomyopathies. J Cell Biol 2008 ; 182 : 35–39. [CrossRef] [PubMed] [Google Scholar]
  12. Bettermann K, Benesch M, Weis S, Haybaeck J. SUMOylation in carcinogenesis. Cancer Lett 2012 ; 316 : 113–125. [CrossRef] [PubMed] [Google Scholar]
  13. Haq R, Fisher DE. Biology and clinical relevance of the micropthalmia family of transcription factors in human cancer. J Clin Oncol 2011 ; 29 : 3474–3482. [CrossRef] [PubMed] [Google Scholar]
  14. Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. Nature 2009 ; 461 : 747–753. [CrossRef] [PubMed] [Google Scholar]
  15. Huang C, Han Y, Wang Y, et al. SENP3 is responsible for HIF-1 transactivation under mild oxidative stress via p300 de-SUMOylation. EMBO J 2009 ; 28 : 2748–2762. [CrossRef] [PubMed] [Google Scholar]
  16. Buscà R, Berra E, Pouysségur J, Ballotti R. HIF1α est une nouvelle cible du facteur de transcription MITF : implication de la cascade AMPc-MITF-HIF1α dans le développement des mélanomes. Med Sci (Paris) 2006 ; 22 : 10–13. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.